Sustained drug-free remission in rheumatoid arthritis associated with diffuse large B-cell lymphoma following tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy using zamtocabtagene autoleucel
David Szabo(Miltenyi Biotec (Germany)), Alexandra Balogh(National Institute of Oncology), László Gopcsa(National Institute of Oncology), Laura Giba-Kiss(National Institute of Oncology), Gergely Lakatos(National Institute of Oncology), Melinda Paksi(National Institute of Oncology), Marienn Réti(National Institute of Oncology), Péter Takács(Miltenyi Biotec (Germany)), Pearl van Heteren(Miltenyi Biotec (Germany)), Gregor Zadoyan(Miltenyi Biotec (Germany)), Silke Holtkamp(Miltenyi Biotec (Germany)), Toon Overstijns(Miltenyi Biotec (Germany)), Stefan Miltenyi(Miltenyi Biotec (Germany)), Péter Reményi(National Institute of Oncology), György Nagy(Semmelweis University)
Cited by 19Open Access
Abstract
We report the case of long-term persisting rheumatoid arthritis (RA), treated with CD20-CD19 CAR-T when it became associated with diffuse large B cell lymphoma (DLBCL), resulting in a sustained drug-free remission of the preceding RA, as well as of the subsequent DLBCL that formed the indication of the CAR-T therapy using zamtocabtagene autoleucel, with a 1-year follow-up. According to our best knowledge, this is the first published clinical case report of long-term persisting RA treated with CAR-T cell therapy.
Related Papers
No related papers found
Powered by citation graph analysis